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Background: Several studies have demonstrated that pa-
tient self-management of oral anticoagulant therapy (OAT)
can improve treatment quality. However, most of these
studies were not conducted within a specialized antico-
agulation care system. The objective of the present study
was to determine whether patient self-management of
OAT improves the quality of care delivered by antico-
agulation clinics.
Methods: In this randomized study by 2 Dutch antico-
agulation clinics 341 patients aged between 18 and 75 years
and receiving long-term OAT were divided into 4 groups:
an existing routine care group of patients untrained in self-
management; a routine care group of trained patients; a
group managed weekly at an anticoagulation clinic where
international normalized ratios were measured by trained
patients; and weekly patient self-management. A 2-step ran-
domization procedure was followed: first, a Zelen-design
randomization was performed to distribute patients (with-
out informing them) to the existing care group or to re-
ceive training in self-management; second, trained pa-
tients were randomized to the 3 other study groups.
Results: Only 25.6% of invited patients agreed to par-
ticipate in the training program. Patients who remained
in the existing care group were within the international
normalized ratio target ränge 63.5% of the time. The
type of coumarin taken was a major predicting factor of
OAT quality. In all study groups phenprocoumon out-
performed acenocoumarol by 11.6% (95% confidence
interval [CI], 6.6%-16.5%). Weekly management with
phenprocoumon led to a 6.5% improvement (95% CI,
0.0%-13.1%) in time in the international normalized
ratio target ränge when patients were managed at an
anticoagulation clinic and to an 8.7% improvement
(95% CI, 1.6%-15.9%) when patients were self-managed.
Weekly management with acenocoumarol did not
improve the quality of OAT.
Conclusion: With selected patients, the quality of OAT
obtained through patient self-management is at least äs
high äs that delivered by specialized physicians at anti-
coagulation clinics. Weekly management of OAT with
long-acting phenprocoumon has to be preferred at an-
ticoagulation clinics or, where possible, through patient
self-management.
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O RAL A N T I C O A G U L A N Ttherapy (OAT) with cou-marin drugs is of vitalimportance in the treat-ment and prophylaxis of
thromboembolic disease. The efficiency
and relative safety of oral anticoagulants
have been proven in clinical studies that
have also led to define different therapeu-
tic ranges for OAT for different indica-
tions. In many cases a minimal interna-
tional normalized ratio (INR) of 2.0 to 2.5
is sufficient for efficient anticoagula-
tion,1"3 but indications with a high throm-
boembolic potential require more inten-
sive anticoagulation. An increase in INR
values is, however, associated with an in-
creased risk of bleeding.4'7 This implies that
strictly maintaining the INR within the
therapeutic ränge is required to ensure
treatment efficacy with the lowest pos-
sible risks of thromboembolic and bleed-
ing complications.
In reality, only 65% to 75% of the INR
values measured during OAT have been
found to be within the target ränge in the
Netherlands,8 where a national network of
anticoagulation clinics is responsible for
the management of OAT.9 This has led to
an improved management of OAT, result-
ing in a decrease in thromboembolic and
bleeding complications. Frequent moni-
toring of prothrombin time (PT)/INR val-
ues continues to be an important part of
the treatment, but it has physical, psycho-
logical, social, and financial conse-
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Study design showing patient numbers at each stage of the selection process.
quences for both patients and the health care System. Many
patients believe that it interferes with their social or work-
ing life, and it is relatively costly and labor intensive for
the health care System.
The development of handheld PT/INR measurement
devices, which determine the PT from capillary whole blood,
has led to the possibility of self-management of OAT. Sev-
eral benefits of patient self-management have already been
put forward by studies in which this new treatment mo-
dality was compared with the existing one.10"16 The poten-
tial advantages of self-management include improved con-
venience for the patients, which leads to better treatment
compliance, more frequent monitoring, and, therefore, im-
proved quality of OAT with fewer thromboembolic and hem-
orrhagic complications.l7 Patient self-management of OAT
is not necessarily less costly than existing care: a training
System needs to be put in place,18·19 while handheld de-
vices and test Strips are expensive. There could be major
cost benefits for the health care System, however, through
a reduction in the number of complications.20
Although these studies have indicated an improve-
ment in the quality of OAT with self-management com-
pared with conventional treatment, the existing System of
treatment delivery mainly consisted of a diversity of treat-
ing physicians instead of a structured and specialized sys-
tem of OAT management. Only l study so far has ana-
lyzed patient self-management in the Dutch System.21 In
that study comparing weekly patient self-management with
weekly management at an anticoagulation clinic, the pa-
tients outperformed the anticoagulation clinics by 6% in
time within the INR target ränge (P= .07). This study was
performed with a highly selected patient group and did
not allow for comparisons with the existing care System.
Performing an objective study comparing patient self-
management of OAT with existing care is difficult. Many
investigators either educate and train patients who are
subsequently randomized for existing care or self-
management, or limit training to the patients random-
ized for self-management. In these designs, compari-
sons between existing care and patient self-management
are obscured by selection and confounding. When pa-
tients are trained for self-management but then return
to the existing care System, this can no longer be defined
äs Standard care owing to patient selection and educa-
tion. When education and training are limited to the pa-
tients selected for self-management, it is unclear whether
subsequently observed effects are caused by patient self-
management itself or by increased patient awareness.
We compared the feasibility, safety, and efficacy of
OAT self-management using the CoaguChek home PT
monitoring device (Röche Diagnostics, Mannheim, Ger-
many)22"24 with the quality of OAT management provided
by the specialized System of Dutch anticoagulation clin-
ics, in a way that evaluates the effect of patient training and
self-management against the background of existing care.
METHÖDS
STUDY DESIGN
This study was performed by 2 Dutch anticoagulation clinics
which, together, are responsible for the OAT of approxi-
mately 18 000 patients per year. All relevant administrative data,
clinical and laboratory parameters, and dosing schedules are
kept in computerized liles arranged according to randomly as-
signed 7-digit patient numbers. From this database we se~
lected eligible patients on the basis of the following criteria: need
for long-term OAT, at least 3 months of OAT experience, and
age between 18 and 75 years. The investigalors checked the pa-
tients' records for eligibility. Exclusion criteria were a diagno-
sis of antiphospholipid syndrome, a life-threatening illness, life
expectancy less than l year, diminished understanding, and
physical limitations making successful participation impos-
sible (eg, dementia or tremors).
The patients were selected from the computer-generated
list of patient numbers by groups of 40 and randomized to 4
treatment groups (A, B, C, and D) following a 2-step partial
Zelen design. The patients randomized to group D were not
informed of the study and therefore served äs an "existing rou-
tine care" control group for whom treatment was not affected
by the study. Patients who were not randomized to group D
were contacted by letter by the investigators and received writ-
ten Information about the study. A return form was included
in which they could indicate their willingness to participate in
the study or give their reasons for declining to do so. If the form
was not returned within 4 weeks, the patients were contacted
by telephone and their reasons for not participating were re-
corded. Those who were willing to participate were invited to
3 training sessions. Cohorts were formed until a total of about
300 patients were actively included in the study, for a goal of
150 patients in group D (nontrained routine care), and 50 trained
patients in groups A, B, and C. After successful training, ran-
domization to groups A, B, or C was revealed lo trainers and
patients. All patients included in the study groups were fol-
lowed up for 26 weeks. Study design and numbers of patients
at each stage of the study are shown in the Figure
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Study protocol and patient Information received ap-
proval from the medical ethics committee of the Leiden Uni-
versity Medical Center prior to the Start of the study.
PATIENT GROUPS
In group A patients agreed to a weekly INR self-measurement
but dosing was performed by anticoagulation clinic physi-
cians. The patients reported their INR values by telephone to
the anticoagulation clinics äs well äs any other relevant Infor-
mation about intercurrent medications, complications, or ill-
nesses. The dosing schedules proposed by the physicians were
sent by fax to the other participating anticoagulation clinic for
correction in case of major mistakes. The patients were then
contacted by telephone about their dosages for the coming week.
In group B, the group for weekly self-management of OAT,
patients informed the anticoagulation clinic of their INR mea-
surements, proposed dosing schedules, and reported any rel-
evant Information about intercurrent medications, complica-
tions, or illnesses. The proposed dosing schedules were sent
by fax to the other anticoagulation clinic for correction in case
of major mistakes. The patients were then contacted by tele-
phone and told whether they could adhere to their proposed
dosing schedule or if they needed to adjust it.
Patients in group C were trained for inclusion in groups A
or B but stayed with the routine care System. Measurements of
INR and dosing were done by anticoagulation clinic physicians,
and the interval between measurements depended on the sta-
bility of the INR values.
Because patients in group D and dosing physicians were
unaware of these patients' participation in the study, group D
fully represented the general population in the existing care
System. Measurements of INR and dosing were done by antico-
agulation clinic physicians, and the intervals between measure-
ments depended on the stability of the INR values.
BLINDING
Knowledge of the composition of the different groups was re-
stricted to a few nurses who were also responsible for anony-
mously transferring the dosing schedules of group A and group
B patients to Standard forms and faxing them to the other par-
ticipating anticoagulation clinic. The physicians evaluating and
correcting the proposed dosing schedules for group A and group
B patients were unaware of the originators of these schedules—
patients in group B or physicians in group A.
The INR values of the patients in routine care groups C
and D were entered into the routine computerized System in
such a way that the dosing physicians could not disünguish
between these and the general patient populalion.
PATIENT EDUCATION
All patients not randomized to group D underwent a training
program consisting of 3 weekly sessions of 90 to 120 minutes.
They received Information about the study, the blood coagu-
lation System, OAT, and the effects of some substances (eg, al-
cohol, certain medications, and foods rieh in vitamin K) on OAT;
then they were taught how to use the CoaguChek device, and
instructed in oral self-dosing of phenprocoumon and aceno-
coumarol.
Training was done in groups of 4 to 5 patients by special-
ized teams consisting of a physician and paramedical person-
nel. A physician was always responsible for self-dosing instruc-
tion and was also present during training with the CoaguChek
device. Teaching staff and patients were made aware of the
groups (A, B, or C) to which patients were randomized only
after the training had been completed.
Before the first training Session the patients were given the
opportunity to view, at home or at the anticoagulation clinic,
a videotape about working with the CoaguChek PT monitor
prepared by the manufacturer.
The first training session contained practical instruction
about working with the CoaguChek PT monitor and informa-
tion about the coagulation System, OAT, and the effects of some
substances on OAT. The patients were given the opportunity
to practice with the device at home during the week between
the first and second training sessions.
During the second training Session the patients had to be
able to perform 2 accurate and reproducible INR measure-
ments with the device unaided by the training staff, and the
results were checked against a laboratory INR measurement from
a venous blood sample. If there were wide differences (>20%)
between laboratory and CoaguChek INR readings, patients were
excluded. Theoretical and practical self-dosing training in OAT
was given in the form of examples of dosing problems. The pa-
tients also received written Information covering all subjects
that had been discussed.
In the third training session self-dosing was discussed with
the aid of practical dosing problems that the patients had pre-
pared at home. Ability to work with the CoaguChek PT moni-
tor was reassessed and randomization to the different patient
groups (A, B, or C) was revealed to training staff and patients
by the other participating anticoagulation clinic. The patients
randomized for inclusion in group B (self-management) re-
ceived a basic dosing schedule upon which they could base their
own future dosage changes.
PT/INR MEASUREMENT
For laboratory PT/INR measurements, venous blood was col-
lected in 105 mEq/L (105 mmol/L) of sodium citrate and plasma
was obtained by centrifugation at 2800g for 10 minutes. To mea-
sure plasma PT, RecombiPlastin reagent (Ortho Diagnostic Sys-
tems, Rariton, NJ) was used with an Elektra 1800 coagulom-
eter (Medical Laboratory Automation, Pleasantville, NY) at the
Leiden anticoagulation clinic, and Innovin reagent (Dade Be-
hring, Liederbach, Germany) was used with an Elektra 1400
coagulometer (Medical Laboratory Automation) at the Oost-
Gelderland anticoagulation clinic. According to international
convention, PT values were expressed äs INR.
For patient PT/INR self-measurement, plasma PT was mea-
sured from a drop of capillary whole blood using the Coag-
uChek PT monitor. This device uses single-use test Strips and
rabbit brain thromboplastin äs a reagent. A reagent master lot
was calibrated by the manufacturer (Röche Diagnostics) against
an international reference preparation for rabbit thromboplas-
tin, and each production lot used in the study was calibrated
against the master lot by the manufacturer. A code chip con-
taining the Information to convert PT into INR values accom-
panies each reagent lot. Lots 104, 129,135, and 180 were used
during the study.
RANDOMIZATION
Randomization was done in 2 steps by the participating anti-
coagulation clinic that the patients did not attend with a table
of random numbers. The goal aimed at was to allot 50 patients
to each of the groups A, B, and C, and 150 patients to group D.
Only after completion of the training program was the inves-
tigating anticoagulation clinic told which patients were ran-
domized to groups A, B, and C.
The first step was patient randomization to group D and
to a non-D group (ie, collectively, the future groups A, B, and
C). The proportion of patients randomized to group D was
changed from 1:3 to 1:10 on the basis of response rates from
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earlier groups. In a subsequent step, consenting patients from
the non-D group were randomized to groups A, B, and C, which
was revealed to the anticoagulation clinic that they did not at-
tend only after training was completed. The ratio for random-
ization into groups A, B, or C was constant at 1:1:1.
DETERMINATION OF OAT DOSING SCHEDULES
Dosing of acenocoumarol and phenprocoumon is normally done
by anticoagulation clinic physicians with the aid of a comput-
erized dosing program (TRODIS; Infotrom, Leiden, the
Netherlands). This program evaluates the stability of INR val-
ues and proposes dosing schedules for about 50% of the pa-
tients. These schedules are then checked by the physicians. For
the other 50% of the patients, no dosage proposal is generated
and dosing is done independently by the physicians. Details of
the dosing algorithm have been published previously.25
This routine dosing method was used for the patients in
groups C and D. Patients in group A received their dosing from
the same physicians but without the use of the Computer al-
gorithm. Dosing was determined on paper, in the way it was
done by the patients themselves in group B.
Therapeutic INR target ranges are defined for all
patients receiving OAT based on their indication for treat-
ment. Two main therapeutic target ranges are used: low-
level anticoagulation when INR values ränge from 2.5 to 3.5,
and high-level anticoagulation when INR values ränge from
3.0 to 4.0.
Only 2 oral anticoagulants are registered in the Nether-
lands: short-acting acenocoumarol (half-life, 11 hours) and long-
acting phenprocoumon (half-life, 140 hours).
END POINTS
The 2 following end points were defined a priori: (1) quality
of OAT was represented by the number of INR readings within
the target ränge, by the time spent within this ränge individu-
ally and per study group, and by the occurrence of thrombo-
embolic or hemorrhagic complications—data concerning com-
plications were gathered from patients, general practitioners,
and regional hospitals; and (2) patients' ablity to indepen-
dently perform anticoagulant self-dosing was considered in-
versely related to the number of dosage corrections made by
the physicians.
STATISTICAL ANALYSIS
To determine OAT quality, INR readings "in ränge" and time
values "in ränge" were used. These were, respectively, the per-
centage of all INR values within the therapeutic target ränge
per patient and the estimated time spent within the thera-
peutic target ränge per patient based on the method of linear
Interpolation. This calculation method has been published
previously.26·27
With more than 1000 INR measurements expected in the
2 main study groups (A and B) and the group representing the
existing System (D) the study was sufficiently powered to de-
tect or exclude differences on the primary outcome. It was un-
derpowered to detect any effects on clinical outcomes other than
the largest, but the study was not primarily envisaged to look
at the effects of the different coumarins.
The number of INR readings in ränge and the time in
ränge are given äs a percentage with 95% confidence intervals
(CIs); the differences and the 95% CIs of the differences are
based on the f distribulion. Linear regression was used to
identify predicting factors. The results of the linear regression
analysis are given äs β levels (standardized) and significance
(P values).
RESULTS
Of the 916 patients randomly selected by Computer, 35
(3.9%) were excluded because of intellectual or physi-
cal limitations or because of a life expectancy of less than
l year.
Of the remaining 881 patients, 161 were random-
ized to control group D and 720 were contacted by a letter
informing them about the study and asking for their par-
ticipation in the training program. Only 184 (25.6%) of these
720 patients agreed to participate, and 536 (74.4%) re-
fused. The reasons for not participating, personal answers
to open questions, are given in the following tabulation:
Reason
Prefers existing System
Too old, nervous, or uncertain
Prefers notto contemplate illness
Personal reasons
Opposed to study design










Training was given to 180 of 184 patients (4 pa-
tients could not find the time). Of these, 21 (11.7%) were
excluded during training for the following reasons: 9 pa-
tients did not succeed in working with the CoaguChek de-
vice, 8 patients had problems with self-dosing, 2 patients
had differences greater than 20% between the laboratory
INR measurement and their CoaguChek results, and 2 pa-
tients did not agree with the randomization process.
Group characteristics are given in Table l. A total
of 319 patients were studied with a mean follow-up time
of 24.4 weeks, for a total of 149.5 patient-years. While the
patients in groups A, B, and C were from the same com-
puter-selected population äs group D, self-selection brought
about differences. The patients in groups A, B, and C were
an average of 7. l years younger than those in group D (95%
CI, 4.7-9.5 years), and groups A, B, and C included more
men than group D. However, linear regression analysis
could not identify age äs a predicting factor for time in ränge
in a model containing age, sex, and type of coumarin
(ß = -0.017;P=.83). Incontrast, the type of coumarin was
a strong predictor for time in ränge (ß = 0.248; P<.001)
in this model. The ratios for the different INR target ranges,
types of coumarin, and indications for OAT differed only
slightly among the different groups. The indication for OAT
was not identified äs an important predicting factor.
The results of the different study groups for the num-
ber of INR readings within the therapeutic ranges (2.5-
3.5 and 3.0-4.0) and the time spent in these ranges, over-
all and stratified by type of coumarin, are given in
Table 2. Overall, time in ränge differed little between
groups, and ranged between 63.5% and 68.6% of the time.
The pattern became different when the type of couma-
rin was taken into account. Patients who used phenproc-
oumon in groups A and B had 72.9% and 75.1% of their
INR readings in ränge, respectively, and clearly outper-
formed patients in control groups C and D who had 69.0%
and 66.3% of their INR readings in ränge. The differ-
ence against the existing System (group D) for time in
ränge with phenprocoumon was 8.7% (95 % CI, 1.6%-
15.9%) for group B (self-management) and 6.5% (95 %CI,
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Table 1. Group Characteristics
Group A: Self-measurement




Mean age, y (ränge)
Target INR ränge, No. (%) of patients
2.5-3.5
3.0-4.0
Anticoagulant, No. (%) of patients
Phenprocoumon
Acenocoumarol









Interval between INR readings, wk (ränge)
No. of INR values
Total follow-up duration, wk




















Group B: Self-measurement Group C:






























































Abbreviations: DVT, deep venous thrombosis; INR, international normalized ratio; PE, pulmonary embolism; TE, thromboembolism.
Tatale 2. Group Results for loternational Normalized Ratio (INR) Readings*
No. of INR readings
Time, wk
General analysis
INR values in ränge
Time in ränge
Phenprocoumon
INR values in ränge
Time in ränge
Acenocoumarol
INR values in ränge
Time in ränge
Group A: Self-measurement




63.9 (59.8 to 68.0)
66.9 (62.7 to 71.0)
69.3 (64.7 to 73.9)
72.9 (68.3 to 77.5)
53.7 (48.0 to 59.4)
55.6 (50.3 to 60.9)
Group B: Self-measurement
of INR Values, Self-dosing
1180
1134
66.3 (61. Oto 71 .5)
68.6 (63.7 to 73.6)
74.0 (68.7 to 79.4)
75.1 (69.6 to 80.6)
51 .7 (44.3 to 59.2)
56.5 (49.4 to 63.6)




61 .3 (55.4 to 67.1)
67.9 (62.9 to 73.0)
63.0(56.9to69.1)
69.0 (63.4 to 74.6)
51. 3 (30.8 to 71. 7)
62.1 (48.2 to 76.1)




58.7 (55.0 to 62.4)
63.5 (59.7 to 67.3)
62.1(57.6to 66.6)
66.3 (61.6 to 71.0)
51 .8 (45.4 to 58.2)








*Values are given äs percentage (95% confidence interval) unless otherwise indicated.
•fP values are determined using analysis of variance for comparison between the 4 groups.
0.01%-13.0%) for group A (self-measurement, dosingby
anticoagulation clinic) (Table 3). For patients taking
acenocoumarol, there was almost no difference in INR
readings in ränge between the groups, although group
C did slightly better than the other groups, with 62.1%.
Combining all groups, the percentages of INR readings
in ränge (8= 12.9%; 95% CI, 7.9%-17.9%) and of time in
ränge (8 = 11.6%; 95% CI, 6.6%-16.5%) were higher with
phenprocoumon than with acenocoumarol.
If we extend the INR target ränge to 2.0 to 4.0, the
ränge that has been used in several studies dealing with
patient self-management, a similar pattern is seen. Group
D, which received the existing Standard of care, was 86.3%
of the time in ränge (88.8% of the time for patients tak-
ing phenprocoumon and 81.1% of the time for patients
taking acenocoumarol). Group B, the self-managed group,
was 91.0% of the time in ränge (94.3% of the time for
patients taking phenprocoumon and 84.8% of the time
for patients taking acenocoumarol).
When we compared, on a weekly basis, the self-
dosing schedules of group A and group B patients with
the schedules determined for them by the anticoagula-
tion clinics' physicians, there was little difference
(Table 4)
The effect of education about the blood coagula-
tion System and OAT was assessed by comparing groups
C (trained patients in general control) and D (general
control). In both groups dosing was done by the antico-
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Table 3. Group Differences in International Normalized Ratio (INR) Values With
Existing System Represented by Group D (Routine Gare) ·
General analysis
INR values in ränge
Time in ränge
Phenprocoumon
INR values in ränge
Time in ränge
Acenocoumarol
INR values in ränge
Time in ränge
Group A: Self-measurement of INR Values,
Dosing by Anticoagulation Clinic
+5.2 (-1.7to 121}




-2.2 (-1 0.1 to 5.7)
Group B: Self-measurement






-1.3 (-10.3 to 7.8)
Group C: Routine Care,
Trained Patients
+2.6 (-4.4 to 9 6)
+4.4 (-2.4 to1 1.3)
+0.9 (-6.8 to 8.6)
+2.6 (-5.2to 10.4)
-0.5 (-17.7to 16.6)
+4.3 (-11. 3 1020.0)
*Values are given äs percentage (95% confidence mterval).
tStatistically significant at P<.05.
Table 4. Comparison of International Normalized Ratio (INR) Readings Between Group A and Group B*
General analysis















Dosing by Anticoagulation Clinic
63.9 (59.8 to 68.0)
66.9 (62 7 to 71.0)
1.0(04to1.7)
0.7 (0.2 to 1.1)
69.3 (64.7 to 73.9)
72.9 (68.3 to 77 5)
0.7 (0.0 to 1.4)
0.5 (0.0 to 1.1)
53.7 (48.0 to 59.4)




of INR Values, Self-dosing
66.3(61.01071.5)
68.6 (63 7 to 73.6)
1.4(0.2to2.6)
0.7 (0.2 to 1.2)
74.0 (68.7 to 79.4)
75.1 (69.6 to 80.6)
0.3 (0.0 to 0.8)
0.4 (0 0 to 0.8)
51 .7 (44.3 to 59.2)
56.5 (49.4 to 63.6)
3.4 (0.1 to 6.7)
1 3 (0 0 to 2.7)
Difference*
2.4 (-4.1 to 8.9)
1.7 (-4.6to 8.4)
0.4 (-0.910 1.7)
0.0 (-0.7 to 0.7)
4.7 (-2.210 11. 6)
2.2 (-4.8 to 9.2)
-0.3 (-1.210 0.5)
-0.2 (-0.9 to 0 5)
1.9 (-10.810 6.9)
0.9 (-7 4 to 9.4)
1.7 (-1.710 5.0)
0.3 (-1.210 1.8)
*Values are given äs percentage (95% confidence mterval)
agulation clinics, with the intervals between INR mea-
surements determined by the stability of the INR (Table
4). The trained patients seemed to have slightly better
results (8 = 4.4%; 95% CI, -2.4% to 11.3%).
Table 5 shows weekly comparisons of INR mea-
sureraents, the intervals between measurements being de-
termined by INR stability and ranging from l to 6 weeks.
Group A (weekly self-measurement) was compared with
group C (group for which INR readings were done every
2.5 to 3.4 weeks). Overall, there was little difference in
time in ränge between the 2 regimens (δ = -1.1%; 95%
CI, -7.5% to 5.4%). When we stratified for the type of
coumarm, however, different patterns emerged. There was
an improvement in time in ränge (8=3.6%; 95% CI, -3.3%
to 11.1%) for patients taking phenprocoumon when mea-
surements and dosing were done on a weekly basis. In
contrast, the weekly dosage change does not appear to
be beneficial with acenocoumarol (8 = -6.5%; 95% CI,
-20.1% to 7.9%).
Dosage corrections by blinded physicians could oc-
cur in groups A (self-measurement, dosing by anticoagu-
lation clinic) and B (self-dosing). Generally, the number
of corrections was low, at 3.7% of all dosage proposals.
There were more dose corrections in group B (5.2%) than
in group A (2.4%). Most corrections concerned minor
changes, and, in retrospect, did not seem necessary.
Major spontaneous hemorrhagic complications were
few. In group B there was l case (0.045/patient-year) of
a spontaneous subdural hematoma, in a patient with stable
INR values in the target ränge during the previous 6 weeks
and no INR values above 3.6 during the previous 18 weeks.
There were 2 cases of gastrointestinal bleeding, l in the
motivated control group C (0.036/patient-year) and l in
the general control group D (0.013/patient-year). There
were 2 cases of traumatic subdural hematoma, l each in
group B and group C. There were no thromboembolic
complications.
COMMENT
The recent development of patient self-management of
OAT has the theoretical benefit of individually tailored
therapy. Patients can adjust their dosing schedules with
a more intimale knowledge of their own behavior and
reactions to dose adjustments. Previous studies have sug-
gested an increased quality of OAT through patient self-
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Table 5. Comparison of International Normalized Ratio (INR) Readlngs Between Group A and Group C*
General analysis















Dosing by Anticoagulation Clinic,
Weekly INR Measurement
63 9 (59.8 to 68.0)
66.9 (62.7 to 71.0)
1.0(0.4to1.7)
0.7 (0.2 to 1.1)
69.3 (64.7 to 73.9)
72.9 (68.3 to 77.5)
0.7 (0.0 to 1.4)
0.5 (0.0 to 1.1)
53 7 (48.0 to 59.4)
55.6 (50.3 to 60.9)
1.7(0.2to3.2)
1.0(0.2to1.8)
Group C: Routine Gare, Trained Patients,
INR Measurement Every 3.3 wk
61. 3 (55.4 to 671)
67.9 (62 9 to 73.0)
0.4 (0.0 to 0.9)
1.3(02to2.3)
63.0 (56.9 to 69.1)
69.0 (63.4 to 74 6)
0.5(00to1.0)
0.8 (0.0 to 1.7)
51 3 (30.8 to 71. 7)
62.1 (48.2 to 76.1)
0.0 (0.0 to 0 0)
4.0(0.0to10.9)
Difference
2.6 (-4 6 to 9.7)
-1.1 (-7.5 to 5.4)




0.2 (-0.7 to 1.1)
-0.3 (-1.3to 0.7)




*Values are given äs percentage (95% confidence interval).
fStatistically signficant at P<.05.
management compared with management by physi-
cians. Our study is the first to compare patient self-
management with management by a highly structured
System of anticoagulation clinics in such a way that sev-
eral aspects, such äs the effect of patient selection and
; education, weekly management, and self-management are
> evaluated independently against the existing System.
In general, INR readings were only around 60% of
the time within the target ränge with the existing rou-
tine System of OAT management. However, this ränge
was relatively narrow. By extending the ränge to 2.0 to
4.0, äs was done in most studies dealing with patient self-
managemenl, readings were within the therapeutic ränge
more than 80% of the time, reflecting the high quality of
routine OAT delivered by specialized anticoagulation clin-
ics. In many of the studies conducted outside of special-
ized care facilities, INR readings were only 40% to 70%
, of the time within target ränge with an existing care de-
livery System.
Patients who consented to participate and received
education had better readings than those in the current
system. Several factors may explam this improvement.
There may be a beneficial effect to increased patient edu-
cation. However, most of the patients who were con-
tacted for participation in the study declined to partici-
pate, and tnerefore the differences could also be attributed
to selection.
It has recently become clear from various studies
done in the Netherlands28"30 that long-acting phenproc-
oumon is associated with a better quality of anticoagu-
lation than short-acting acenocoumarol. In the 4 study
groups, the results with phenprocoumon use were su-
perior to those with acenocoumarol use.
Can more frequent INR measurements, and conse-
quently the possibility of more frequent dosage adjust-
ments, improve the quality of OAT? In this study we looked
at the effect of fixed weekly readings and dosing com-
pared with that of INR readings and dosing about every 3
weeks depending on INR stability. There was a clear ad-
vantage to a weekly System for patients using phenproc-
oumon, contrasting with an important loss in time in ränge
with weekly dosing of acenocoumarol. Weekly dosage cor-
rections of short-acting acenocoumarol may create more
numerous and stronger fluctuations in INR values than
the wider-spaced corrections needed with long-acting phen-
procoumon. It may be that fluctuations, which are inher-
ent in a treatment with acenocoumarol, are further in-
creased by frequent dose corrections. It is logical to prefer
using the longer-acting and less fluctuating drug and avoid
large dose adjustments.
In this study the largest improvements in time in
ränge, compared with those obtained by the existing Sys-
tem, were reached with a combination of patient educa-
tion and use of phenprocoumon, dosed weekly by anti-
coagulation clinic Professionals and—with even better
results—by patients themselves. From our results it is clear
that selected patients are capable of delivering to them-
selves at least the same quality of OAT äs the specialized
anticoagulation clinics would deliver to them under the
same conditions (ie, weekly INR measurements and dos-
ing), and that they can even improve on it. Theoretically,
one would expect the patients to be more able to tailor treat-
ment to their individual circumstances. Our study had a
follow-up of only 26 weeks, and it would be expected that
the quality of self-management improves äs patients be-
come more experienced and learn more about their indi-
vidual responses to dose changes.
Many of the patients in the self-management group
opted to continue with this mode of treatment at the end
of the study period, with visits to the anticoagulation clinic
every 3 months. Taking into account the low percentage
of participation in this study and the reasons for not par-
ticipating, it is clear that self-management is a valid al-
ternative treatment modality only for a relatively small
proportion of anticoagulation clinic patients: younger,
more active individuals possibly more attuned to Infor-
mation technology and receiving long-term anticoagu-
lation. The quality of patient training and the availabil-
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ity of medical and paramedical backup are of course crucial
for the success of patient self-management In this study
patients underwent a ngorous trammg program and re-
ceived intensive support from the mvestigators, which
might not be available at most regulär treatment facili-
ties It is clear that regulär evaluation visits to the anti-
coagulation chnics are advisable
In conclusion, this study has shown that patient self-
management of OAT is an efficient and safe treatment mo-
dahty m the Netherlands Under the nght conditions and
for selected patients, self-management can provide an im-
provement m the quahty of OAT currently dehvered by
anticoagulation chnics Optimal-control OAT can be de-
fmed äs a treatment with phenprocoumon rather than
acenocoumarol This treatment is based on frequent PT/
INR measurements, which can easily be performed by the
patients themselves with the aid of a home PT monitor and,
where possible, managed by well-trained and well-
supported patients who can adapt OAT to their particular
circumstances and needs For most patients, however, this
treatment of choice must be received at speciahzed anti-
coagulation chnics
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